Hot Features
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anae... Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | -0.00214 | -15.2857142857 | 0.014 | 0.0182 | 0.0106 | 33609 | 0.0158003 | CS |
| 12 | -0.00094 | -7.34375 | 0.0128 | 0.0182 | 0.0105 | 60003 | 0.01334121 | CS |
| 26 | -0.00294 | -19.8648648649 | 0.0148 | 0.0189 | 0.0105 | 40498 | 0.01387918 | CS |
| 52 | -0.00024 | -1.98347107438 | 0.0121 | 0.0309 | 0.0089 | 40243 | 0.01514431 | CS |
| 156 | -0.01114 | -48.4347826087 | 0.023 | 0.0755 | 0.0089 | 139448 | 0.03141776 | CS |
| 260 | -0.67712 | -98.2786147639 | 0.68898 | 0.91 | 0.0089 | 103313 | 0.08713944 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.